| Literature DB >> 28442878 |
Rodrigo Pirmez1, Juan Piñeiro-Maceira2,3, Carmen Gloria Gonzalez4, Mariya Miteva5.
Abstract
Erlotinib is a selective epidermal growth factor receptor inhibitor utilized in the treatment of solid tumors. Cutaneous side effects, including changes in hair texture and alopecia, have been described. In this case report, we describe two patients with a new finding of loose anagen hairs and pili torti leading to nonscarring marginal and diffuse alopecia and discuss potential mechanisms underlying erlotinib-induced hair changes.Entities:
Keywords: Adverse drug reaction; alopecia; erlotinib; loose anagen hair; lung cancer; pili torti; scalp disease; side effects; trichoscopy
Year: 2016 PMID: 28442878 PMCID: PMC5387882 DOI: 10.4103/ijt.ijt_16_16
Source DB: PubMed Journal: Int J Trichology ISSN: 0974-7753
Figure 1Pronounced nonscarring alopecia along the entire hair margin in (a) patient one and (b) patient two; (c) patient two after 3-month therapy
Figure 2Trichoscopic and histopathologic findings in patients treated with erlotinib. Trichoscopy shows (a) black dots, twisting of hair shafts, and broken hairs at different lengths (×20); (b) features resembling black rectangular granular structures (×20); (c) high magnification of a flattened hair shaft reveals multiple twisting (×250); (d) the pull test results in numerous anagen hairs devoid of sheaths (×250); (e) scalp biopsy from the alopecic area shows two hair follicles corresponding to the broken hairs on trichoscopy as their hair shafts are replaced by pigmented casts in the hair canal and are surrounded by abnormal, disintegrated inner root sheath, and irregularly thinned outer root sheath. Note the absence of sebaceous glands (H and E, vertical sections, ×4); (f) two anagen follicles at the level of subcutaneous fat reveal corrugated and thicker pink vitreous layer (H and E, horizontal sections, ×10)